Status:
COMPLETED
Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Conditions:
Attention-Deficit/Hyperactivity Disorder
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
The objective of this study is to evaluate the long-term effects and tolerability of ABT-089 in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
Eligibility Criteria
Inclusion
- The subject was randomized into Study M10-346 and completed the study.
- Female subjects of childbearing potential must have a negative urine pregnancy test at screening and baseline and agree to comply with applicable contraceptive requirements.
- Male subjects must agree to comply with applicable contraceptive requirements.
- The subject is judged to be in generally good health.
Exclusion
- The subject has taken any ADHD medication between the last dose of study drug in Study M10-346 and the first dose of study drug in the current study.
- The subject anticipates a move outside the geographic area.
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
117 Patients enrolled
Trial Details
Trial ID
NCT00686933
Start Date
May 1 2008
End Date
October 1 2008
Last Update
January 21 2013
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Reference ID/Investigator# 8315
Lafayette, California, United States, 94549
2
Site Reference ID/Investigator# 8306
Jacksonville, Florida, United States, 32216
3
Site Reference ID/Investigator# 8308
Orlando, Florida, United States, 32806
4
Site Reference ID/Investigator# 8314
Overland Park, Kansas, United States, 66212